Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Titel:
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Auteur:
Jones, Robert H Casbard, Angela Carucci, Margherita Cox, Catrin Butler, Rachel Alchami, Fouad Madden, Tracie-Ann Bale, Catherine Bezecny, Pavel Joffe, Johnathan Moon, Sarah Twelves, Chris Venkitaraman, Ramachandran Waters, Simon Foxley, Andrew Howell, Sacha J
Verschenen in:
Lancet oncology
Paginering:
Jaargang 21 () nr. 3 pagina's 345-357
Jaar:
2020
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license